News | June 24, 2024
Ascentage Pharma closes US$ 75 million equity investment by Takeda
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
These abstracts report on the company's three lead drug candidates, including olverembatinib
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications
Subscribe To Our Newsletter & Stay Updated
